Sunday 18 October 2026 Export IKT’s income statement to Excel — free account

Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022. In the quarter to June 2026, EPS was flat and free cash flow fell 123.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

1.65 0.18 −9.84%

Follow IKT

Alert me

Market cap: $255.4M
P/E: 0.0×
Fwd P/E: −2.6×
Dividend yield: —
F-score: 3/9
Altman Z: −8.82
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 3.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 37.93%

Capital & Financial Ratios $m

Market Cap 255.35

Revenue 0.26

Net Income (60.64)

Free Cash Flow (42.61)

Net Debt (159.02)

Current Ratio 15.82

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.62)

P/S ratio 1,105.73

P/B ratio 1.88

Past 5Y EPS Growth —

This Y EPS Growth 11.33%

Next Y EPS Growth (5.72%)

Next Y revenue growth 3,216.70%

Next 5Y EPS Growth 6.39%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 91.44%

10-year low 10-year high

P/B against its own 10 years 69.66%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	13	98	179	159
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	0	0	1	2
	14	98	180	162

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	3	—
	3	4	8	10

Compound Annual Growth %

	10y	5y	3y
Sales	—	(42.21%)	(28.02%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	77.60%	101.81%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’23	0	0	0	0	0
’22	0	0	0	0	0
’21	1	1	0	0	3
’20	0	0	0	0	1
’19	—	—	—	0	1
’18	—	—	—	—	4

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(12)	—	—	—
’25	(4)	(6)	(11)	(8)	(28)
’24	(4)	(5)	(5)	(5)	(19)
’23	(6)	(5)	(4)	(3)	(18)
’22	(4)	(4)	(6)	(4)	(17)
’21	(4)	(4)	(2)	(4)	(14)
’20	0	0	0	(1)	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(12)	—	—	—
’25	(4)	(6)	(11)	(8)	(28)
’24	(4)	(5)	(5)	(5)	(19)
’23	(6)	(5)	(4)	(3)	(18)
’22	(4)	(4)	(6)	(4)	(18)
’21	(4)	(4)	(2)	(4)	(14)
’20	0	0	0	(1)	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.10)	(0.11)	—	—	—
’25	(0.15)	(0.11)	(0.13)	(0.09)	(0.49)
’24	(0.73)	(0.66)	(0.65)	0.88	(1.16)
’23	(0.96)	(1.11)	(0.86)	(0.63)	(3.57)
’22	(1.08)	(1.08)	(1.08)	(1.02)	(4.32)
’21	(1.56)	(1.32)	(1.08)	(1.20)	(4.86)
’20	(0.40)	(0.31)	(0.49)	(0.90)	(2.10)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	38.52	8.16	2.64	0.79	1.12	1.33	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	70.80	54.96	10.80	6.94	4.20	3.49
People
People	Employees	—	—	—	2	3	7	7	9	16	35
	Revenue/emp, $m	—	0.00	0.00	0.56	0.23	0.44	0.02	0.03	0.00	0.00
Income, $m
Income, $m	Revenue	—	2	4	1	1	3	0	0	—	—
	Gross margin, %	—	0.00	100.00	100.00	100.00	100.00	100.00	100.00	—	—
	EBT	—	0	(2)	(6)	(3)	(15)	(18)	(19)	(28)	(48)
	EBT margin, %	—	(21.16)	(53.27)	(509.75)	(407.72)	(476.88)	(14,630.63)	(7,304.76)	0.00	0.00
	Net income	—	0	(2)	(6)	(3)	(15)	(18)	(19)	(28)	(48)
	Depreciation	—	—	—	—	—	—	0	0	0	0
Per share, $
Per share, $	Revenue	—	0.20	3.02	0.82	0.51	1.02	0.03	0.04	0.00	0.00
	Earnings	—	(0.04)	(1.61)	(4.20)	(2.10)	(4.86)	(4.32)	(3.57)	(1.16)	(0.49)
	Cash flow	—	(0.01)	0.54	(0.25)	(0.82)	(4.71)	(4.11)	(3.00)	(0.81)	(0.28)
	Capex	—	0.00	0.00	0.00	0.00	0.00	(0.06)	0.00	0.00	0.00
	Free cash flow	—	(0.01)	0.54	(0.25)	(0.82)	(4.71)	(4.17)	(3.00)	(0.81)	(0.28)
	Book value	—	(0.14)	(0.58)	(3.29)	7.15	12.66	4.98	1.82	4.00	1.76
	Shares, m	—	10	1	1	1	3	4	6	24	98
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—
	P/S	—	105.66	105.66	105.66	81.92	8.63	111.13	30.78	—	—
	P/B	—	0.00	0.00	0.00	5.85	0.70	0.65	0.73	—	—
	EV/Sales	—	105.65	105.65	105.65	61.93	(4.51)	(75.51)	(20.10)	—	—
	EV/FCF	—	(155.88)	(155.88)	(155.88)	(38.30)	0.98	0.53	0.29	—	—
Cash, $m
Cash, $m	Operating cash flow	—	0	1	0	(1)	(14)	(17)	(18)	(19)	(28)
	Capex	—	—	—	—	—	—	0	0	—	0
	Free cash flow	—	0	1	0	(1)	(14)	(18)	(18)	(19)	(28)
Balance, $m
Balance, $m	Working capital	—	(2)	(2)	(4)	10	38	21	11	95	172
	Total debt	—	0	0	0	0	0	0	—	—	—
	Net debt	—	0	0	0	(14)	(41)	(23)	(13)	(98)	(179)
	Shareholders’ equity	—	(1)	(1)	(4)	10	38	21	11	95	173
Returns, %
Returns, %	ROA	—	(27.85)	(151.24)	(396.78)	(38.43)	(51.65)	(53.57)	(96.49)	(48.66)	(34.49)
	ROIC	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	39.31	194.01	217.27	(107.58)	(61.35)	(60.74)	(118.88)	(52.00)	(36.05)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Dec 2023

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ABEO Abeona Therapeutics Inc.	$265.9M	— (loss-making)	— (loss-making)	+225.14% (above 0%: growing)	n/m	+17.11% (above 0%: growing)	63.30%	(119.97%)	Compare
PRLD Prelude Therapeutics Incorporated	$265.0M	— (loss-making)	— (loss-making)	+42.60% (above 0%: growing)	n/m	+40.32% (above 0%: growing)	100.00%	(270.93%)	Compare
CABA Cabaletta Bio, Inc.	$262.8M	— (loss-making)	—	—	n/m	−35.72% (below 0%: shrinking)	0.00%	0.00%	Compare
XFOR X4 Pharmaceuticals, Inc.	$261.8M	— (loss-making)	— (loss-making)	+346.33% (above 0%: growing)	n/m	+13.76% (above 0%: growing)	81.64%	(186.13%)	Compare
RCKT Rocket Pharmaceuticals, Inc.	$259.1M	— (loss-making)	—	—	n/m	+19.16% (above 0%: growing)	0.00%	0.00%	Compare
VNDA Vanda Pharmaceuticals Inc.	$256.4M	— (loss-making)	— (loss-making)	−3.92% (below 0%: shrinking)	n/m	−101.02% (below 0%: shrinking)	92.95%	(126.28%)	Compare
IKT Inhibikase Therapeutics, Inc.	$255.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−123.23% (below 0%: shrinking)	0.00%	0.00%
LCTX Lineage Cell Therapeutics, Inc.	$250.5M	— (loss-making)	— (loss-making)	−61.34% (below 0%: shrinking)	n/m	−32.40% (below 0%: shrinking)	100.00%	(834.71%)	Compare
ACIU AC Immune	$249.4M	— (loss-making)	— (loss-making)	+29.66% (above 0%: growing)	n/m	+4.66% (above 0%: growing)	100.00%	(1,321.50%)	Compare
Median of peers	$260.4M	—	—	+36.13%	—	+9.21%	87.30%	(156.20%)

All 614 Biotechnology stocks →

Inhibikase Therapeutics, Inc. (IKT) key facts

Strength: Inhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022.
Inhibikase Therapeutics, Inc. (IKT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IKT traded at $1.65, a market capitalization of $255.4 million.
Return on equity was −36.1% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −8.82 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.